Abstract
The primary objective of our research was to examine the influence of the long non-coding RNA UNC5B-AS1 (lncRNA UNC5B-AS1) on the advancement of glioma. We assessed the expression of lncRNA UNC5B-AS1 using bioinformatic analysis, quantitative reverse transcription polymerase chain reaction (qRT-PCR), and in vivo experimental verification. Bioinformatic analysis revealed that elevated expression of lncRNA UNC5B-AS1 was indicative of unfavourable prognosis in gliomas. Furthermore, a noteworthy association was observed between lncRNA UNC5B-AS1 and the transforming growth factor-beta (TGF-β) pathway in gliomas. Further analysis of clinical specimens and cell lines validated a substantial upregulation of lncRNA UNC5B-AS1 in gliomas in comparison to normal tissues. in vivo and in vitro experimentation supported the notion that disrupting the expression of lncRNA UNC5B-AS1 could impede the proliferation of glioma and facilitate apoptosis. Further studies have shown that lncRNA UNC5B-AS1 aggravated tumor progression by promoting the expression of TGF-β in gliomas. The selective dual inhibitor of TGF-β receptor type I/II (TβRI/II), LY2109761, significantly inhibited the tumor growth induced by the upregulation of TGF-β mediated by lncRNA UNC5B-AS1.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
